Unknown Infection & Immunity NIHR-supported project Digestion, Kidneys & Other Organs

COVID-19:Prospective analysis of sero-prevalence and risk factors in inflammatory bowel disease (IBD) patients on maintenance biological therapy.

Funder NIHR (part of DHSC)
Recipient organisation NIHR Oxford Biomedical Research Centre
NIHR support Recorded as supported by this research centre
Period Apr 2025 — Ongoing

About this grant

This summary is based on the grant title only — the full abstract was not available.

No substantive source abstract was published for this research project funded by NIHR.

Researchers

Jack Satsangi (Principal Investigator)

Related Research

Grants with similar aims, by meaning.

CRF461- CLARITY Impact of biologic and immunomodulatory therapy on Sars-COV-2 infectin and immunity in patients with inflammatory bowel disease
Open IBD: A longitudinal multi-omics inception cohort in inflammatory bowel disease
Impact Of Biologic And Immunomodulatory Therapy On Sars-Cov-2 Infection And Immunity In Patients With Inflammatory Bowel Disease.
CLARITY IBD (impaCt of bioLogic therApy on saRs-cov-2 Infection and immuniTY, ISRCTN45176516, www.clarityibd.org ) is a UK NIHR COVID-19 urgent public health study.
ImpaCt of bioLogic therApy on saRs-cov-2 Infection and immuniTYCLARITY

Original classification

Inflammation across Tissues

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.